Tryptophan-derived microbial metabolites activate the aryl hydrocarbon receptor in tumor-associated macrophages to suppress anti-tumor immunity
The aryl hydrocarbon receptor (AhR) is a sensor of products of tryptophan metabolism and a potent modulator of immunity. Here, we examined the impact of AhR in tumor-associated macrophage (TAM) function in pancreatic ductal adenocarcinoma (PDAC). TAMs exhibited high AhR activity and Ahr-deficient ma...
Saved in:
Published in | Immunity (Cambridge, Mass.) Vol. 55; no. 2; pp. 324 - 340.e8 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Elsevier
08.02.2022
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The aryl hydrocarbon receptor (AhR) is a sensor of products of tryptophan metabolism and a potent modulator of immunity. Here, we examined the impact of AhR in tumor-associated macrophage (TAM) function in pancreatic ductal adenocarcinoma (PDAC). TAMs exhibited high AhR activity and Ahr-deficient macrophages developed an inflammatory phenotype. Deletion of Ahr in myeloid cells or pharmacologic inhibition of AhR reduced PDAC growth, improved efficacy of immune checkpoint blockade, and increased intra-tumoral frequencies of IFNγ⁺CD8⁺ T cells. Macrophage tryptophan metabolism was not required for this effect. Rather, macrophage AhR activity was dependent on Lactobacillus metabolization of dietary tryptophan to indoles. Removal of dietary tryptophan reduced TAM AhR activity and promoted intra-tumoral accumulation of TNFα⁺IFNγ⁺CD8⁺ T cells; provision of dietary indoles blocked this effect. In patients with PDAC, high AHR expression associated with rapid disease progression and mortality, as well as with an immune-suppressive TAM phenotype, suggesting conservation of this regulatory axis in human disease. NRC publication: Yes |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 AUTHOR CONTRIBUTIONS T.L.M. designed and supervised the research. K.H., R.S., S.L., M.T.C., E.G.F., D.C., L.N., K.L., P.M., X.Z., and I.C. executed the biochemical, cell biological, and in vitro experiments. M.J.H., K.H., and S.L. performed the animal experiments. A.K. and R.Q. analyzed the RNA-seq results. G.H.J. analyzed the TCGA data and T.J.P. performed the pan-cancer TCGA analysis. D.P. conducted and analyzed the mass spectrometry data and interpreted the results. H.M. analyzed the 16S rRNA-sequencing data. A.M., B.G., R.K., P.S.O., G.O., S.G., W.W.N., D.P., and D.G.B. contributed reagents, human samples, and discussions. K.H., R.S., A.K., M.J.H., R.Q., M.T.C., T.J.P., D.P., G.J., H.M., and T.L.M. prepared figures and conducted statistical analysis and T.L.M. wrote the paper. |
ISSN: | 1074-7613 1097-4180 1097-4180 |
DOI: | 10.1016/j.immuni.2022.01.006 |